ADVANZ PHARMA Corp. ADVANZ PHARMA is a global pharmaceutical company determined to deliver sustainable value across our portfolio of products in the global specialty off patent sector.

Contact Information:
Adam Peeler 
Tel: 905-842-5150 x 240
Adam.Peeler@advanzpharma.com

Latest

07:00 ET ADVANZ PHARMA Corp. Comments on CMA Statement of Objections Related to Prochlorperazine

MISSISSAUGA, ON, May 23, 2019 /CNW/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare...


May 10, 2019, 07:00 ET ADVANZ PHARMA Corp. Announces First Quarter 2019 Results

First quarter 2019 revenue of $136 million First quarter 2019 net loss of $8 million First quarter 2019 Adjusted EBITDA1 of $65 million Generated cash flow from operations of $46 million in the first ...


Apr 26, 2019, 07:00 ET ADVANZ PHARMA Corp. Announces Release Date for First Quarter 2019 Results

MISSISSAUGA, ON, April 26, 2019 /CNW/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients...


Apr 01, 2019, 07:00 ET ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines

Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus...


Mar 14, 2019, 07:00 ET ADVANZ PHARMA Corp. Announces Fourth Quarter and Fiscal 2018 Results

2018 revenue of $537 million, fourth quarter 2018 revenue of $118 million 2018 net income of $1.5 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's transaction...


Feb 21, 2019, 07:00 ET ADVANZ PHARMA Corp. Announces Release Date for Fourth Quarter and 2018 Results

MISSISSAUGA, ON, Feb. 21, 2019 /CNW/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients...


Jan 30, 2019, 07:30 ET ADVANZ PHARMA Corp. Comments on CMA Supplemental Statement of Objections

MISSISSAUGA, ON, Jan. 30, 2019 /CNW/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on helping innovate, shape and grow ...


Nov 29, 2018, 17:00 ET Concordia International Corp. Announces Name Change to ADVANZ PHARMA Corp.

MISSISSAUGA, ON, Nov. 29, 2018 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing...


Nov 14, 2018, 07:00 ET Concordia International Corp. Announces Third Quarter 2018 Results

Third quarter 2018 revenue of $128 million Third quarter net income of $1.8 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's recently completed transaction to...


Oct 31, 2018, 17:00 ET Concordia International Corp. Announces Release Date for Third Quarter 2018 Results

MISSISSAUGA, ON, Oct. 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Oct 29, 2018, 08:30 ET Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors

MISSISSAUGA, ON, Oct. 29, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Oct 15, 2018, 17:00 ET Concordia International Corp. Announces Addition of Pharmaceutical Industry Expert to its Board of Directors

MISSISSAUGA, ON, Oct. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Oct 09, 2018, 07:00 ET Concordia International Corp. Announces Intention To Rebrand As ADVANZ PHARMA Following Its Successful Recapitalization

- ADVANZ PHARMA represents the Company's vision to go beyond expectations to bring sustainable value to customers, healthcare providers, and patients - MISSISSAUGA, ON, Oct. 9, 2018 /CNW/ - Concordia ...


Oct 05, 2018, 16:30 ET Concordia International Corp. Announces Special Meeting of Shareholders To Approve Name Change

MISSISSAUGA, ON, Oct. 5, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Sep 12, 2018, 07:48 ET Concordia International Corp. Provides Further Update On Its Recently Completed Recapitalization Transaction and the Issue Price of its Private

MISSISSAUGA, ON, Sept. 12, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) issued a further announcement today, at the request of the Investment Industry...


Sep 11, 2018, 13:18 ET Concordia International Corp. Provides Update On Its Recently Completed Recapitalization Transaction

MISSISSAUGA, ON, Sept. 11, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Sep 06, 2018, 21:05 ET Concordia International Corp. Completes Recapitalization Transaction

MISSISSAUGA, ON, Sept. 6, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in...


Aug 13, 2018, 17:20 ET Concordia International Corp. Announces Update on its Recapitalization Transaction, Filing of Certain Documents in connection with the Implementation

MISSISSAUGA, ON, Aug. 13, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that in connection with the previously announced recapitalization...


Aug 08, 2018, 07:00 ET Concordia International Corp. Announces Second Quarter 2018 Results

- Also Announces Executive Leadership Transition - Second quarter 2018 revenue of approximately $139 million Second quarter 2018 GAAP net loss of $180 million Second quarter 2018 Adjusted EBITDA1 of...


Jul 25, 2018, 07:00 ET Concordia International Corp. Announces Release Date for Second Quarter 2018 Results

Company also provides anticipated timing update for closing of its Recapitalization Transaction MISSISSAUGA, ON, July 25, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company")...


Jul 19, 2018, 07:00 ET Concordia International Corp. Announces NASDAQ Delisting

Concordia previously announced delisting notice on May 31, 2018 MISSISSAUGA, ON, July 19, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international...


Jun 26, 2018, 10:00 ET Concordia International Corp. Obtains Final Court Order Approving its Recapitalization Transaction and Announces Leadership Changes

OAKVILLE, ON, June 26, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European ...


Jun 19, 2018, 12:49 ET Concordia International Corp. Announces Approval of its CBCA Plan of Arrangement by its Shareholders and Debtholders

OAKVILLE, ON, June 19, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) today announced that at the meetings (the "Debtholders' Meetings") of holders of certain...


Jun 18, 2018, 08:40 ET Concordia International Corp. Announces Amendments to its CBCA Plan of Arrangement in Connection with its Recapitalization Transaction

OAKVILLE, ON, June 18, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that, in connection with the previously announced proposed recapitalization ...


May 31, 2018, 07:00 ET Concordia International Corp. Provides Corporate Update

OAKVILLE, ON, May 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a...